# Efficacy and Safety of ACH24 in the Treatment of Vitiligo

> **NCT01419964** · PHASE3 · WITHDRAWN · sponsor: **Ache Laboratorios Farmaceuticos S.A.**

## Conditions studied

- Vitiligo

## Interventions

- **DRUG:** Group 01
- **DRUG:** Group 02

## Key facts

- **NCT ID:** NCT01419964
- **Lead sponsor:** Ache Laboratorios Farmaceuticos S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-01
- **Primary completion:** 2013-12
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The Brazilian regulatory agency - ANVISA has requested the cancellation of the phase 3 study for conducting a phase 1 study first.
- **Last updated:** 2016-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01419964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01419964, "Efficacy and Safety of ACH24 in the Treatment of Vitiligo". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01419964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*